I recently attended the Alliance for Regenerative Medicine's Cell & Gene Meeting on the Med, the leading conference bringing together the ATMP community from Europe and beyond to cover a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector.
Over the course of my time at the meeting, three themes emerged:
1. The regenerative medicine sector is hotter than ever. On the heels of an already remarkable year for cell & gene therapies, 2024 could deliver as many as 14 new cell & gene approvals in the US and EU. Watch this space.
2. Following the path of CAR-T, we are on the cusp of realizing the potential for more complex cell types. It’s inspiring to see where CAR-T is today as compared to where it was 5-10 years ago, particularly as it relates to standardization of CMC, nonclinical and clinical approaches. We will soon see a similar inflection for more complex cell types, like the work we do at Satellite with hepatocytes, which has the potential to deliver an incredible impact for patients.
3. And speaking of patients – they are waiting. Having the opportunity to hear directly from the people and caregivers whose lives have been changed by regenerative medicines inspires the work we do every day; and is an important reminder to keeping pushing forward.
If you missed it (and are registered) be sure to check out my presentation here: https://informaconnect.com/cel...
